International Journal of Financial Management and Economics

P-ISSN: 2617-9210
E-ISSN: 2617-9229
IJFME 2025; 8(1): 417-420
www.theeconomicsjournal.com
Received: 20-04-2025
Accepted: 26-05-2025

Urvi Nikhil Kumar
IIT, Kanpur, Uttar Pradesh, India

Corresponding Author:
Urvi Nikhil Kumar
IIT, Kanpur, Uttar Pradesh, India

Regulatory hurdles in India's pain relief industry

Urvi Nikhil Kumar

DOI: https://www.doi.org/10.33545/26179210.2025.v8.i1.523

Abstract
India's pain relief industry faces significant regulatory challenges at each stage of product development, from company registration to product launch. This paper analyzes the various hurdles encountered by startups in the sector, highlighting the regulatory acts involved and estimating the time delays at each stage. Through an in-depth examination of the process from company registration, product classification, clinical trials, intellectual property protection, manufacturing, and supply chain compliance, to marketing, this study aims to provide a comprehensive overview of the regulatory landscape for startups in the pain relief sector. The paper concludes with an estimate of the total time required for a product to reach the market in India and recommends potential reforms for streamlining the regulatory process.

Keywords: Pain Relief Industry, Regulatory Hurdles, India, Narcotic Regulations, Licensing Procedures, Drug Policy, Pharmaceutical Sector, CDSCO, NDPS Act, Pain Management, Healthcare Regulations, Opioid Accessibility, Compliance Challenges, Global Regulatory Comparison, Pain Medication Misuse, Pharmaceutical Governance, Startup Challenges, Regulatory Barriers for Startups, Pain Relief Startups, Market Entry Challenges, Innovation in Pain Management, Startup Funding in Healthcare, MedTech Startups, HealthTech Regulations, Pharmaceutical Startups, FDA India Regulations, Drug Approval Process, Entrepreneurship in Healthcare

1. Introduction
The current status in India shows a high need for healthcare support, especially for the pain relief products such as pharmaceutical painkillers, along with alternative treatments such as herbal medicines and nutraceuticals. The market for the pain relief products shows evaluation in the current period as the Indian market also illustrates a high awareness about pain relief options and the rise in chronic diseases. However, despite the vast potential and demand for such products, startups in India face significant regulatory hurdles and these further reduce the scope for pain relief product's development and commercialisation process.

A complex set of laws and act governs the regulatory framework for healthcare products in India, and it also includes the Drugs and Cosmetics Act, 1940, the Food Safety and Standards Act, 2006, and various guidelines from the Ministry of AYUSH for herbal products. These regulations have crucial purposes such as a proper focus on three crucial aspects about the health products; the safety, quality, and efficacy. However, they also create bottlenecks in the product development process, especially for new and emerging companies with poor resources or expertise for the navigation purposes in the regulatory compliance maze.

The startup faces versatile challenges and these are stages from the product development cycle, company registration, product classification, regulatory approvals acquisition, clinical trials formulation, intellectual property protection, manufacturing, along with product launch. For instance, regulatory approvals for new drugs or pain relief products may take months or even years, as it may involve bureaucratic delays and complications in product classification. Moreover, the complexities in intellectual property protection, particularly in the innovative pain relief formulation cases, further extend the time to market.

This paper aims to comprehensively examine the regulatory hurdles for the startups in India's pain relief industry. It will analyze the challenges from each stage in the product development process, from company registration, marketing and launch. The paper will

provide valuable insights into the inefficiencies in the regulatory system and suggest potential solutions for streamlining the process, after the time delays estimation at each stage and comparison among the regulatory environment in India and other countries.

2. Literature Review

Multiple laws and regulations govern the Indian pharmaceutical industry, along with the pain relief sector. These regulations have crucial purposes and these involve a high focus on the safety, efficacy, and quality for health products, however, they also present significant barriers to entry for new businesses. The regulatory environment shows fragment nature and also illustrates overlapping responsibilities among central and state agencies. Thus, issues such as these often lead to delays and inefficiencies in the approval process.

Several studies highlight the challenges startups face in the approvals acquisition process from the Central Drugs Standard Control Organization (CDSCO) and the Food Safety and Standards Authority of India (FSSAI), especially for the classification in pain relief products as drugs or nutraceuticals. The product launch phase face delays as the trials in the clinic and property protection takes adequate time in the pain relief industry.

3. Analysis of Regulatory Hurdles

3.1 Company Registration & Business Setup

Startups from India needs to focus on crucial steps such as registration process as it includes versatile legal attributes. These stages are simple but often takes a high time for the completion process. The process takes a long time as it includes versatile government procedures.

- **The Companies Act, 2013**

The company incorporation process includes multiple steps and these are name approval, registration with the relevant authorities such as "Registrar of Companies", and a digital signature certificate acquisition. This procedure often takes a few weeks for completion but may also face delays in case any legal or compliance issues arise.

- **Startup India Registration**

The entrepreneurs have a high need for criteria fulfilment and these are innovation, scale measurement, and potential for employment generation. These criteria are crucial as it induces the scope for startup's qualification process under the Startup India Initiative. The startup registration process also includes crucial steps such as documentation and relevant authorities also review these documents. Therefore, these steps further contribute to delays.

- **GST Registration & Licensing**

Goods and Services Tax (GST) registration and the necessary business licenses acquisition is essential for the business operation in India. Although, the GST registration process is simple, business permits acquisition may take time. The time for permit attainment is high, in case the business has operations in multiple states.

Estimated Time Delay: 2-3 months

3.2 Product Classification & Regulatory Approvals

Pain relief products' classification is crucial and startup companies also need to follow correct regulations in this scenario. The proper regulation is essential as it determines the approval type and identify the responsible regulatory bodies. The classification process may create confusion, as products may fall into different categories, such as pharmaceutical drugs, nutraceuticals, or herbal remedies.

- **Drugs and Cosmetics Act, 1940**:

In case a product falls under the drug category, it requires approval from the "Drugs Controller General of India (DCGI)". This includes safety tests and efficacy tests, and often involves additional documentation, product sample formulation, and tests in laboratory.

- **FSSAI Regulations**

It is important to comply with the "Food Safety and Standards Authority of India (FSSAI)" for the status with pain relief products from the nutraceutical category. The requirements in regulation is less strict for nutraceuticals than for pharmaceutical drugs, but they still require a long approval process.

- **AYUSH Ministry Regulations**

Products from Ayurvedic or traditional medicine fall under the "Ministry of AYUSH's" jurisdiction. These products fall under specific guidelines and these may include traditional use's documentation, clinical trials, and production standards.

Estimated Time Delay: 6-12 months (as per the product classification confusion)

3.3 Clinical Trials & Safety Testing

Clinical trials are necessary for new pain relief formulations, such as novel drugs or treatments, as it is useful to assess the product's safety and efficacy. The regulation for the clinical trials in India has purposes and these include a proper alignment with high standards before the approval process for sale.

- **New Drugs and Clinical Trials Rules, 2019**

These rules mandates, new drugs undergo clinical trials in India before the advertisement process. The process for ethics committee's approval acquisition, patient recruitment, and trial formulation may take a long time and increase expenditures.

- **Good Manufacturing Practice (GMP) Compliance**

Manufacturers must focus on "**Good Manufacturing Practices (GMP)"** as it is helpful to ensure products' safety and quality standards. The proper alignment with GMP standards is essential as it is necessary for the production approval.

- **Ethics Committee Approvals**

An ethics committee's approval is necessary for the trails in clinics and especially for the trial with human participants. This process often adds delays, as trials involve complex procedures or large sample sizes.

Estimated Time Delay: 1-2 years

3.4 Intellectual Property & Brand Protection

Intellectual property (IP) protection is crucial for startups from the pain relief industry as it is helpful to safeguard

their innovations. However, IP rights acquisition or patent acquisition and trademarks may take a long time in India and this may result in delays.

- **Indian Patent Act, 1970**:

Patents acquisition for new pain relief formulations or technologies may take several years as the Indian Patent Office conducts an extensive examination process. Patents for novel formulations often take 3-5 years for approval.

- **Trademarks Act, 1999**

A trademark registration for brand protection is crucial step for startups. The registration process may face delays as crucial challenges such as legal disputes or challenges may occur in the trademark proposal.

Estimated Time Delay: 6 months - 2 years

3.5 Manufacturing & Supply Chain Compliance

Startups with production plants need to comply with regulations for environment, health, and safety in the pain relief industry as it is mandatory for in India.

- **Environmental Protection Act, 1986**

Production facilities must comply with environmental regulations for air and water quality, waste disposal, and emissions. Compliance with these regulations is necessary for the operation license attainment.

- **Import-Export Code (IEC) Registration**

Startups with pain relief product export goals needs to focus on an "Import-Export Code (IEC)" attainment from the "Directorate General of Foreign Trade". This code is necessary for customs clearance and also facilitates international trade.

Estimated Time Delay: 3-6 months

3.6 Marketing & Product Launch Restrictions

Once the product is ready for launch, startups must comply with various regulations about advertisement.

- **Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954**

This Act restricts the health products' advertisement, especially for the products with improver claims about the impacts.

- **Legal Metrology Act, 2009**

The **Legal Metrology Act** is important as it shows, all products need accurate labels with information about ingredients, instructions for use, and expiry dates. This may increase time as the requirements from the regulatory authorities include versatile details.

Estimated Time Delay: 3-6 months

4. Conclusion

Startups in the pain relief industry face challenges such as proper knowledge about the regulations in the India. The regulations in India includes company registration, product classification, clinical trials, intellectual property protection, production compliance, and advertisement restrictions—and this may lead to delays in the product development for the market. Startups in the pain relief industry may face issues such as delays as the Indian government promotes versatile regulations for the innovation process. These regulations may act as hurdles for the firms and in this process, may also increase business costs, or create uncertain situations in the market entry.

As per the analysis process from this paper, it is clear, the approval process for the versatile regulations for pain relief product in India takes a long time such **2 to 6 years.** It depends on various factors such as the product's classification, the clinical trials' complex nature, and intellectual property challenges. As per the best-case scenario the time for product launch is 2-3 years, and customer may acquire a product in 4-5 years. The worst-case scenario shows a product launch after 6 years as the company may face delays for approval or disputes.



Fig 1: Timeline of Estimated Delay in Each Phase

These delays in the timeline poses challenge for the startups as it may reduce the scope for stable funds and sustainable business practices. The delays may also slow down the crucial product introduction with life-saving capacity. The complex government regulation for product safety, quality is a challenge as it can reduce the scope for flexible business practices. Therefore, the delays can also act as barrier and reduce the scope to fulfil the demand for large pain relief

medications in India.

To foster innovation and reduce time-to-market, it is essential for regulatory authorities in India to consider streamlining the approval processes. Simplifying the classification procedures for new products, providing clearer guidelines for clinical trials, and enhancing support for startups in navigating intellectual property protection could substantially reduce delays. Additionally, increased transparency and communication between startups and regulatory bodies can help mitigate the uncertainty that startups face when planning their product development timelines.

As per the challenges, future research may focus on the assessment about reformation in the government regulation. Apart from this, the future research may also focus on the safety concerns, and the need for market access in time. Furthermore, digital technology's role such as AI's importance for trails in clinic, blockchain technology for supply chain also needs a proper attention. A proper focus on these aspects is necessary as it may highlight bottlenecks in the government regulations for the startups.

As per the conclusion, India's pain relief sector has a high potential for growth, however the production process and product delivery to end users takes a long time. Startups may focus on these delays and government bodies may also work towards a streamline environment creation. The environment may also show a support towards the innovation, entrepreneurship as it is crucial for the growth in the pain relief medicine production sector.

5. References

1. Indian Pain Society. "Chronic Pain Statistics in India." Retrieved from https://www.indianpainsociety.org
2. Government of India, Ministry of Corporate Affairs. "The Companies Act, 2013." Retrieved from https://www.mca.gov.in
3. Government of India, Ministry of Commerce & Industry. "Startup India Registration." Retrieved from https://www.startupindia.gov.in
4. Goods and Services Tax (GST) Council. "GST Registration Process." Retrieved from https://www.gst.gov.in
5. Central Drugs Standard Control Organization (CDSCO). "Drugs and Cosmetics Act, 1940." Retrieved from https://cdsco.gov.in
6. Food Safety and Standards Authority of India (FSSAI). "FSSAI Regulations for Nutraceuticals." Retrieved from https://www.fssai.gov.in
7. Ministry of AYUSH, Government of India. "Regulations for Ayurvedic Products." Retrieved from https://www.ayush.gov.in
8. Ministry of Health and Family Welfare. "New Drugs and Clinical Trials Rules, 2019." Retrieved from https://www.mohfw.gov.in
9. Indian Council of Medical Research (ICMR). "Good Manufacturing Practices (GMP)." Retrieved from https://www.icmr.gov.in
10. National Ethical Review Board. "Ethics Committee Guidelines for Clinical Trials." Retrieved from https://www.nethicsboard.org
11. Government of India, Ministry of Commerce & Industry. "Indian Patent Act, 1970." Retrieved from https://www.ipindia.gov.in
12. Intellectual Property India. "Trademark Registration Process." Retrieved from https://www.ipindia.gov.in
13. Ministry of Environment, Forest and Climate Change. "Environmental Protection Act, 1986." Retrieved from https://www.moef.gov.in
14. Directorate General of Foreign Trade. "Import-Export Code Registration." Retrieved from https://www.dgft.gov.in
15. Ministry of Health and Family Welfare. "Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954." Retrieved from https://www.mohfw.gov.in
16. Legal Metrology Department. "Legal Metrology Act, 2009." Retrieved from https://www.legislation.gov.in